Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun 21;383(9935):2168-79.
doi: 10.1016/S0140-6736(13)61903-0. Epub 2014 Feb 26.

Cholangiocarcinoma

Nataliya Razumilava  1 , Gregory J Gores  2
Affiliations
Review

Cholangiocarcinoma

Nataliya Razumilava et al. Lancet. .

Abstract

Cholangiocarcinoma represents a diverse group of epithelial cancers united by late diagnosis and poor outcomes. Specific diagnostic and therapeutic approaches are undertaken for cholangiocarcinomas of different anatomical locations (intrahepatic, perihilar, and distal). Mixed hepatocellular cholangiocarcinomas have emerged as a distinct subtype of primary liver cancer. Clinicians need to be aware of intrahepatic cholangiocarcinomas arising in cirrhosis and properly assess liver masses in this setting for cholangiocarcinoma. Management of biliary obstruction is obligatory in perihilar cholangiocarcinoma, and advanced cytological tests such as fluorescence in-situ hybridisation for aneusomy are helpful in the diagnosis. Liver transplantation is a curative option for selected patients with perihilar but not with intrahepatic or distal cholangiocarcinoma. International efforts of clinicians and scientists are helping to identify the genetic drivers of cholangiocarcinoma progression, which will unveil early diagnostic markers and direct development of individualised therapies.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Integrative approach to (A) diagnosis and (B) individualised medicine in cholangiocarcinoma
FISH=fluorescence in-situ hybridisation. SDS-PAGE=sodium dodecyl sulfate polyacrylamide gel electrophoresis.
Figure 2
Figure 2. Potential cells of origin in intrahepatic cholangiocarcinoma
PV=portal vein. HA=hepatic artery. BD=bile duct. HC=hepatic cell.
Figure 3
Figure 3. Approach to management of (A) intrahepatic and (B) perihilar cholangiocarcinoma
HCC=hepatocellular carcinoma. CA 19-9=carbohydrate antigen 19-9. Reproduced with modifications from reference 69 by permission of Elsevier.
Figure 4
Figure 4. Imaging studies of a patient with perihilar cholangiocarcinoma of the left hepatic duct
Note prominent left hepatic duct dilatation with obstruction of the left hepatic duct system on the CT scan (A), MRI (B), endoscopic retrograde cholangiography (C), and magnetic resonance cholangiography (D); (D) also shows bilateral obstruction of the biliary system at the right and left hepatic bile duct confluence.
See this image and copyright information in PMC

Comment in

References

    1. Razumilava N, Gores GJ. Combination of gemcitabine and cisplatin for biliary tract cancer: a platform to build on. J Hepatol. 2011;54:577–78. - PubMed
    1. Nakanuma Y, Sato Y, Harada K, Sasaki M, Xu J, Ikeda H. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol. 2010;2:419–27. - PMC - PubMed
    1. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008;48:308–21. - PMC - PubMed
    1. DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245:755–62. - PMC - PubMed
    1. Komuta M, Govaere O, Vandecaveye V, et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology. 2012;55:1876–88. - PubMed

Publication types